Logos Global Management
Latest statistics and disclosures from Logos Global Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are CYTK, APLS, SRPT, IDYA, ARGX, and represent 40.99% of Logos Global Management's stock portfolio.
- Added to shares of these 10 stocks: ARGX (+$55M), SRPT (+$48M), RYZB (+$35M), APLS (+$33M), CYTK (+$31M), Ambrx Biopharma (+$30M), GPCR (+$23M), INBX (+$23M), OCUL (+$18M), MOR (+$15M).
- Started 19 new stock positions in LIFE, INBX, SLRN, MLTX, ZNTL, EWTX, Tourmaline Bio, KNSA, MORF, Ambrx Biopharma. FULC, NMRA, SLN, ARGX, RNA, RYZB, OCUL, APLT, RCUS.
- Reduced shares in these 10 stocks: ICVX (-$39M), BBIO (-$24M), RCKT (-$21M), , IMVT (-$17M), IDYA (-$16M), CERE (-$15M), ROIV (-$14M), XENE (-$14M), MRTX (-$13M).
- Sold out of its positions in ALXO, Ambrx Biopharma, BBIO, CERE, CRNX, ETNB, GERN, GRCL, KALV, LPTX. LIAN, MRTX, NBIX, RYTM, SLNO, TYRA, VERV, VIGL, ROIV, ZURA, IMTX, MRUS.
- Logos Global Management was a net buyer of stock by $123M.
- Logos Global Management has $1.1B in assets under management (AUM), dropping by 42.93%.
- Central Index Key (CIK): 0001792126
Tip: Access up to 7 years of quarterly data
Positions held by Logos Global Management consolidated in one spreadsheet with up to 7 years of data
Download as csv Download as ExcelPortfolio Holdings for Logos Global Management
Logos Global Management holds 50 positions in its portfolio as reported in the December 2023 quarterly 13F filing
Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
---|---|---|---|---|---|---|
Cytokinetics Com New (CYTK) | 12.7 | $136M | +30% | 1.6M | 83.49 |
|
Apellis Pharmaceuticals (APLS) | 10.9 | $117M | +39% | 2.0M | 59.86 |
|
Sarepta Therapeutics Call Option (SRPT) | 6.3 | $68M | +250% | 700k | 96.43 |
|
Ideaya Biosciences (IDYA) | 6.0 | $64M | -20% | 1.8M | 35.58 |
|
Argenx Se Sponsored Adr (ARGX) | 5.1 | $55M | NEW | 145k | 380.43 |
|
Olema Pharmaceuticals (OLMA) | 5.1 | $54M | +17% | 4.4M | 12.40 |
|
Immunovant (IMVT) | 4.7 | $51M | -25% | 1.2M | 42.13 |
|
Structure Therapeutics Sponsored Ads (GPCR) | 4.1 | $44M | +114% | 1.1M | 40.76 |
|
Rocket Pharmaceuticals (RCKT) | 3.6 | $38M | -35% | 1.3M | 29.97 |
|
Rayzebio (RYZB) | 3.3 | $35M | NEW | 568k | 62.17 |
|
Ambrx Biopharma | 2.8 | $30M | NEW | 2.1M | 14.24 |
|
Karuna Therapeutics Ord (KRTX) | 2.7 | $29M | -21% | 90k | 316.51 |
|
Immunocore Hldgs Ads (IMCR) | 2.6 | $27M | -11% | 400k | 68.32 |
|
Dyne Therapeutics (DYN) | 2.3 | $25M | -13% | 1.9M | 13.30 |
|
Morphosys Sponsored Ads Call Option (MOR) | 2.3 | $25M | +160% | 2.5M | 9.90 |
|
Inhibrx Call Option (INBX) | 2.1 | $23M | NEW | 600k | 38.00 |
|
Annexon (ANNX) | 2.1 | $23M | -6% | 5.0M | 4.54 |
|
Akero Therapeutics (AKRO) | 1.7 | $19M | +33% | 800k | 23.35 |
|
Ocular Therapeutix (OCUL) | 1.7 | $18M | NEW | 4.0M | 4.46 |
|
Design Therapeutics (DSGN) | 1.2 | $13M | 5.0M | 2.65 |
|
|
Miragen Therapeutics (VRDN) | 1.2 | $13M | -42% | 600k | 21.78 |
|
Edgewise Therapeutics (EWTX) | 1.0 | $10M | NEW | 950k | 10.94 |
|
Revolution Medicines (RVMD) | 0.9 | $10M | +40% | 350k | 28.68 |
|
Acelyrin (SLRN) | 0.9 | $9.3M | NEW | 1.3M | 7.46 |
|
Moonlake Immunotherapeutics Class A Ord (MLTX) | 0.8 | $9.1M | NEW | 150k | 60.39 |
|
Atyr Pharma Com New (LIFE) | 0.8 | $8.2M | NEW | 5.9M | 1.41 |
|
Iovance Biotherapeutics Call Option (IOVA) | 0.8 | $8.1M | 1.0M | 8.13 |
|
|
Fulcrum Therapeutics (FULC) | 0.8 | $8.1M | NEW | 1.2M | 6.75 |
|
Allakos (ALLK) | 0.7 | $7.9M | -37% | 2.9M | 2.73 |
|
Zentalis Pharmaceuticals Call Option (ZNTL) | 0.7 | $7.6M | NEW | 500k | 15.15 |
|
Tourmaline Bio | 0.7 | $7.4M | NEW | 284k | 26.18 |
|
Avidity Biosciences Ord (RNA) | 0.7 | $7.0M | NEW | 775k | 9.05 |
|
Silence Therapeutics Ads (SLN) | 0.6 | $6.9M | NEW | 400k | 17.37 |
|
Xenon Pharmaceuticals (XENE) | 0.6 | $6.9M | -66% | 150k | 46.06 |
|
Neumora Therapeutics (NMRA) | 0.6 | $6.5M | NEW | 382k | 17.05 |
|
Arcus Biosciences Incorporated (RCUS) | 0.6 | $6.2M | NEW | 325k | 19.10 |
|
Morphic Hldg (MORF) | 0.5 | $5.8M | NEW | 200k | 28.88 |
|
Applied Therapeutics (APLT) | 0.5 | $5.6M | NEW | 1.7M | 3.35 |
|
Ventyx Biosciences (VTYX) | 0.5 | $4.9M | +788% | 2.0M | 2.47 |
|
Icosavax (ICVX) | 0.4 | $4.7M | -89% | 300k | 15.76 |
|
Repare Therapeutics Ord (RPTX) | 0.4 | $4.4M | -25% | 600k | 7.30 |
|
Compass Pathways Sponsored Ads (CMPS) | 0.4 | $4.4M | -47% | 500k | 8.75 |
|
Enliven Therapeutics (ELVN) | 0.4 | $4.2M | 307k | 13.84 |
|
|
Astria Therapeutics (ATXS) | 0.4 | $4.2M | 545k | 7.68 |
|
|
Spyre Therapeutics Com New (SYRE) | 0.3 | $3.2M | -28% | 150k | 21.52 |
|
Kiniksa Pharmaceuticals Com Cl A (KNSA) | 0.2 | $2.6M | NEW | 150k | 17.54 |
|
Delcath Sys Com New (DCTH) | 0.1 | $1.2M | -71% | 300k | 4.16 |
|
Io Biotech (IOBT) | 0.1 | $928k | 494k | 1.88 |
|
|
Immunic (IMUX) | 0.1 | $632k | 421k | 1.50 |
|
|
Nuvation Bio *w Exp 07/07/202 (NUVB.WS) | 0.0 | $4.0k | 67k | 0.06 |
|
Past Filings by Logos Global Management
SEC 13F filings are viewable for Logos Global Management going back to 2019
- Logos Global Management 2023 Q4 filed Feb. 14, 2024
- Logos Global Management 2023 Q3 filed Nov. 14, 2023
- Logos Global Management 2023 Q2 filed Aug. 14, 2023
- Logos Global Management 2023 Q1 filed May 15, 2023
- Logos Global Management 2022 Q4 filed Feb. 14, 2023
- Logos Global Management 2022 Q3 filed Nov. 14, 2022
- Logos Global Management 2022 Q2 filed Aug. 15, 2022
- Logos Global Management 2022 Q1 filed May 16, 2022
- Logos Global Management 2021 Q4 filed Feb. 14, 2022
- Logos Global Management 2021 Q3 filed Nov. 15, 2021
- Logos Global Management 2021 Q2 restated filed Aug. 17, 2021
- Logos Global Management 2021 Q2 filed Aug. 16, 2021
- Logos Global Management 2021 Q1 filed May 17, 2021
- Logos Global Management 2020 Q4 filed Feb. 16, 2021
- Logos Global Management 2020 Q3 restated filed Nov. 17, 2020
- Logos Global Management 2020 Q3 filed Nov. 16, 2020